A Novel Nomogram to Predict Prognosis of Advanced Hepatocellular Carcinoma Treated with Intensity-Modulated Radiotherapy Plus Anti-PD1
Meiling He,Chunfeng Liang,Yadan Pang,Mengjie Jiang,Meiying Long,Zhongqiang Yao,Xiaoting Wang,Ruijun Zhang,Qiaoyuan Wu,Shixiong Liang,Jianxu Li
DOI: https://doi.org/10.2147/jhc.s459683
2024-05-23
Journal of Hepatocellular Carcinoma
Abstract:Meiling He, 1 Chunfeng Liang, 1 Yadan Pang, 1 Mengjie Jiang, 1 Meiying Long, 2 Zhongqiang Yao, 3 Xiaoting Wang, 1 Ruijun Zhang, 1 Qiaoyuan Wu, 1 Shixiong Liang, 1 Jianxu Li 1 1 Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, 530021, People's Republic of China; 2 School of Public Health, Guangxi Medical University, Nanning, 530021, People's Republic of China; 3 Department of General Affairs, Guangxi Medical University Cancer Hospital, Nanning, 530021, People's Republic of China Correspondence: Shixiong Liang; Jianxu Li, Tel +86 13917716605 ; +86 18878732921, Email ; Purpose: The combination of radiotherapy and monoclonal antibody against programmed cell death 1 (anti-PD1) showed preliminary efficacy in hepatocellular carcinoma (HCC). This study aimed to identify the prognostic factors and construct a nomogram to predict the overall survival (OS) of patients with advanced HCC after treatment with intensity-modulated radiotherapy (IMRT) plus anti-PD1. Patients and Methods: The OS and progression-free survival (PFS) of 102 patients with BCLC stage C HCC was analyzed using the Kaplan-Meier method. Potential independent prognostic factors were determined using univariate and multivariate Cox regression analyses. A nomogram was established to predict prognosis whose accuracy and reliability was verified by a calibration curve and area under the receiver operating characteristic curve (AUROC). Results: The median PFS and OS rates of the 102 patients with advanced HCC were 9.9 months and 14.3 months, respectively. Ninety-three patients were evaluated for efficacy, including five (5.38%) with complete response and 48 (51.61%) with partial response, with an overall response rate of 56.99%. Grade 3 and 4 adverse reactions (AEs) were observed in 32.35% of patients; no grade 5 AEs occurred. Multivariate Cox analysis revealed albumin and alpha-fetoprotein levels, neutrophil counts 3– 4 weeks after IMRT initiation, and platelet-to-lymphocyte ratio 3– 4 weeks after IMRT initiation to be independent prognostic factors. The nomogram model constructed using these factors had good consistency and accuracy with 1– 3 years AUROC of 78.7, 78.6, and 93.5, respectively. Conclusion: IMRT plus anti-PD1 showed promising efficacy and controllable adverse reactions in treating advanced HCC. The nomogram model demonstrated good reliability and clinical applicability. Plain Language Summary: The combination of radiotherapy and monoclonal antibody against programmed cell death 1 (anti‐PD1) showed preliminary efficacy and manageable safety in HCC. We retrospectively evaluated the efficacy and safety of 102 patients with advanced HCC treated with intensity-modulated radiotherapy (IMRT) plus anti-PD1. The study shows that the combination showed promising efficacy with a median PFS and OS of 9.9 months and 14.3 months, respectively. The adverse reactions were controllable. The novel nomogram model established based on independent prognostic factors including albumin, alpha-fetoprotein, neutrophils count 3– 4 weeks after IMRT initiation and platelet-to-lymphocyte ratio 3– 4 weeks after IMRT initiation demonstrated good reliability. Keywords: hepatocellular carcinoma, advanced, intensity-modulated radiotherapy, antibody against programmed cell death 1, nomogram Hepatocellular carcinoma (HCC) is the sixth most common malignancy and fourth leading cause of cancer death globally. 1 Half of these cases occur in China, making it the fourth most common malignant tumor in China, with the second-highest fatality rate among all cancers. 2 Of these, 53.6% patients with HCC are diagnosed in advanced stage with poor prognosis. 3 Sorafenib and lenvatinib were recommended as the first-line therapy for unresectable HCC, which has median overall survival (OS) and median progression-free survival (PFS) of 10.7 months, 5.5 months and 13.6 months, 7.4 months, respectively. 4,5 In comparison, the median OS and PFS of atezolizumab plus bevacizumab were 19.2 months, 6.8 months, with better OS and PFS outcomes. 6 However, the treatment outcomes in patients with advanced HCC remain unsatisfactory. Radiotherapy (RT) is a highly effective anticancer therapy that can achieve local control rates between 30% and 50% in advanced HCC. 7 In recent years, monoclonal antibodies against programmed cell death 1 pathway (anti‐PD1) have been shown to have a positive therapeutic effect in patients with advanced HCC, with an overall response rate (ORR) of approximately 14–17%. 8–10 Anti‐PD1 can regulate tumor immune environment, -Abstract Truncated-
oncology